Robert W. Holloway, MD, FACOG, FACS

Co-Medical Director, Florida Hospital Gynecological Oncology

Biographical Sketch

As Co-Medical Director of Florida Hospital Gynecologic Oncology, Dr. Holloway has earned the respect of his colleagues as a consultant gynecologic oncologist and gynecologic surgeon. In 2007 Dr. Holloway was named “Surgeon of the Year” by the Orange County Medical Society and each year since 2005 he has been voted “Best Doctor” in Orlando by his peers.

Dr. Holloway is recognized internationally for his robotic surgery skills. He routinely travels as a course director and speaker at robotic symposia including university programs in South America, Europe, and Japan.  American and International surgeons frequently attend advanced training courses at Florida Hospital under his direction, and post-graduate Fellows in the 3-year gynecologic oncology training program at Florida Hospital graduate with expert surgical skills in the management of gynecologic cancer and complex benign pathology.

As a recognized expert in gynecologic oncology, Dr. Holloway is a featured presenter at GOG, ASCO, and SGO national conferences. In pursuit of medical excellence, Dr. Holloway is the principal investigator for several clinical trials and research projects. In collaboration with Florida Hospital PhD scientists, he actively participates in the basic research of novel therapies for ovarian cancer that may soon progress to phase I clinical trials for patients with recurrent disease. Dr. Holloway publishes scientific articles regularly and is an associate editor for the Journal of Robotic Surgery

Professional Highlights

• Co-Medical Director,
  Florida Hospital Gynecologic Oncology

• Adjunct Clinical Professor, Department of Obstetrics and Gynecology
  Duke Comprehensive Cancer Center, Durham, NC

• Professor of Obstetrics and Gynecology, University of Central Florida, Orlando, FL

Education & Fellowships

Fellowship: Georgetown University Hospital, Washington D.C.

Residency: University of Alabama at Birmingham, Obstetrics and Gynecology

Medical School: Vanderbilt University, Nashville, TN

Undergraduate: University of Illinois, Champaign-Urbana

Accreditation

• American Board of Obstetrics and Gynecology
• American Board of Obstetrics and Gynecology, Gynecologic Oncology Certification
• Fellowship American College Obstetrics and Gynecology
• Fellowship American College Surgeons

Areas of Specialty

• Radical pelvic surgery and reconstruction
• Robotic assisted hysterectomy and lymphnadectomy for gynecologic cancers
• Robotic assisted surgery for advanced, complex benign disease (endometriosis, leiomyomata, adnexal masses, and complex hyperplasia)
• Investigational therapeutics for advanced ovarian cancer

Professional Memberships

• American College of Obstetrics and Gynecology 
• Society of Gynecologic Oncologists 
• American College of Surgeons
• American Society of Clinical Oncology
• Charles E. Flowers Medical Society
• Florida Association of Clinical Oncology
• Florida Society of Gynecologic Oncologists

Research & Publications

Dr. Holloway has authored and coauthored more than 74 abstracts and publications to date, including:

Holloway RW, Ahmad S, DeNardis SA, Peterson LB, Sultana N, Bigsby IV GE, Pikaart DP, Finkler NJ. Robotic-assisted laparoscopic hysterectomy with lymphadenectomy for endometrial cancer: Analysis of surgical performance. Gynecol. Oncol., 2009; 115:447-452

Holloway RW, Patel SD, Ahmad S. Robotic surgery in gynecology. Scand. J. Surg. 2009; 98: 96-109.

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 113: 21-27, 2009.

Mendivil A, Holloway RW, Boggess JF. Emergence of robotic assisted surgery in gynecologic oncology. Gynecol. Oncol. 2009; 114 (2 Suppl.): S24-31.

Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, Holloway RW, Edwards JR. Synergistic cytotoxicity of interferon-a2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy. Gynecol. Oncol. 2009; 112: 192-198.